We are live on
!
Find out more
PFM
Privium Fund Management Portfolio holdings
AUM
$480M
1-Year Est. Return
77.45%
This Fund
S&P 500
This Quarter
Est. Return
-13.18%
1 Year Est. Return
+77.45%
3 Year Est. Return
+410.34%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$480M
AUM Growth
-$62.8M
(-12%)
Cap. Flow
+$19.4M
Cap. Flow
% of AUM
4.03%
Top 10 Holdings %
Top 10 Hldgs %
63.98%
Holding
64
New
7
Increased
24
Reduced
17
Closed
4
Top Buys
| 1 |
Esperion Therapeutics
ESPR
|
+$10.4M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$5.38M |
| 3 |
Denali Therapeutics
DNLI
|
+$5.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$4.16M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$3.88M |
Top Sells
| 1 |
Biogen
BIIB
|
+$5.47M |
| 2 |
Merck
MRK
|
+$3.85M |
| 3 |
Tesla
TSLA
|
+$2.68M |
| 4 |
Arrowhead Research
ARWR
|
+$1.98M |
| 5 |
VZLA
Vizsla Silver
VZLA
|
+$1.12M |
Sector Composition
| 1 | Healthcare | 33.85% |
| 2 | Consumer Discretionary | 24.98% |
| 3 | Technology | 24.21% |
| 4 | Financials | 8.49% |
| 5 | Communication Services | 6.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Alnylam Pharmaceuticals
ALNY
$37.3B
| $4.04M | 0.84% |
+12,222
| New | +$4.16M |
|
27
Viridian Therapeutics
VRDN
$2.09B
| $3.39M | 0.71% |
173,516
| – | – |
|
28
Krystal Biotech
KRYS
$10.1B
| $2.89M | 0.6% |
11,170
-1,000
| -8% | -$266K |
|
29
Ambev
ABEV
$48.2B
| $2.77M | 0.58% |
948,558
-114,616
| -11% | -$328K |
|
30
Zai Lab
ZLAB
$2.19B
| $2.49M | 0.52% |
132,189
| – | – |
|
31
BioNTech
BNTX
$22.8B
| $2.4M | 0.5% |
27,000
-6,300
| -19% | -$647K |
|
32
enGene Therapeutics
ENGN
$126M
| $2.4M | 0.5% |
352,087
| – | – |
|
33
CRISPR Therapeutics
CRSP
$4.92B
| $2.04M | 0.42% |
42,874
| – | – |
|
34
MeiraGTx Holdings
MGTX
$1.15B
| $1.84M | 0.38% |
212,112
+12,112
| +6% | +$92K |
|
35
Wave Life Sciences
WVE
$1.16B
| $1.75M | 0.36% |
241,010
+48,000
| +25% | +$625K |
|
36
Stoke Therapeutics
STOK
$1.82B
| $1.63M | 0.34% |
50,000
-5,000
| -9% | -$164K |
|
37
4D Molecular Therapeutics
FDMT
$598M
| $1.59M | 0.33% |
170,256
-39,744
| -19% | -$346K |
|
38
Beam Therapeutics
BEAM
$3.17B
| $1.52M | 0.32% |
63,982
-7,518
| -11% | -$209K |
|
39
Moderna
MRNA
$26.4B
| $1.52M | 0.32% |
29,994
-19,600
| -40% | -$914K |
|
40
Pfizer
PFE
$138B
| $1.48M | 0.31% |
52,679
+14,929
| +40% | +$397K |
|
41
Lexeo Therapeutics
LXEO
$367M
| $1.18M | 0.25% |
205,000
+12,450
| +6% | +$88.2K |
|
42
Cartesian Therapeutics
RNAC
$259M
| $1.1M | 0.23% |
179,114
+6,614
| +4% | +$47.1K |
|
43
Molina Healthcare
MOH
$12.6B
| $1.09M | 0.23% |
+8,140
| New | +$1.3M |
|
44
Sarepta Therapeutics
SRPT
$1.92B
| $1M | 0.21% |
46,000
+3,000
| +7% | +$58.1K |
|
45
SLB Ltd
SLB
$70.9B
| $948K | 0.2% |
18,451
-20,354
| -52% | -$988K |
|
46
Rocket Pharmaceuticals
RCKT
$405M
| $867K | 0.18% |
242,146
+72,000
| +42% | +$286K |
|
47
Hims & Hers Health
HIMS
$8.06B
| $830K | 0.17% |
40,000
| – | – |
|
48
Taysha Gene Therapies
TSHA
$1.63B
| $813K | 0.17% |
181,900
+17,000
| +10% | +$79K |
|
49
NOV
NOV
$6.84B
| $791K | 0.16% |
42,026
-11,100
| -21% | -$208K |
|
50
Transocean
RIG
$5.89B
| $707K | 0.15% |
106,604
-33,000
| -24% | -$186K |
|
Similar funds
FCM
DA
YLHM
BFA
HC
LIM
TAA
NQWM